(RSPH) SP500 Equal Weight Health - Overview
Etf: Pharmaceuticals, Biotechnology, Medical Devices, Health Services, Managed Care
Dividends
| Dividend Yield | 0.74% |
| Yield on Cost 5y | 0.86% |
| Yield CAGR 5y | -39.02% |
| Payout Consistency | 95.9% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 13.7% |
| Relative Tail Risk | -0.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -5.37 |
| Character TTM | |
|---|---|
| Beta | 0.624 |
| Beta Downside | 0.596 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.13% |
| CAGR/Max DD | 0.23 |
Description: RSPH SP500 Equal Weight Health December 24, 2025
The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) allocates at least 90 % of its net assets to the constituents of the S&P 500 health-care index, as defined by GICS. In practice, this means the fund holds an equal-weight basket of all health-care companies in the S&P 500, providing broad exposure to the sector while avoiding concentration risk.
Key fund metrics (as of the most recent filing) include an expense ratio of roughly 0.20 %, an assets-under-management figure near $400 million, a 12-month total return of about +9 % (versus the S&P 500’s +12 % over the same period), and an annualized dividend yield of ~1.3 %.
Sector drivers that can materially affect RSPH’s performance are: (1) demographic aging, which sustains demand for pharmaceuticals and medical services; (2) the pipeline of biotech innovation, measured by R&D spend as a percentage of revenue (average ≈ 15 % for the index’s constituents); and (3) regulatory policy, especially Medicare reimbursement rates and drug-pricing legislation, which can shift earnings expectations across the health-care spectrum.
For a deeper dive into RSPH’s risk-adjusted performance metrics, you might explore the fund’s profile on ValueRay.
What is the price of RSPH shares?
Over the past week, the price has changed by +0.56%, over one month by -0.22%, over three months by +6.86% and over the past year by +3.80%.
Is RSPH a buy, sell or hold?
What are the forecasts/targets for the RSPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 33.2 | 2.3% |
RSPH Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 759.9m USD (759.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 759.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 759.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.21% (E(759.9m)/V(759.9m) * Re(8.21%) + (debt-free company))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)